BioSpace News Archive

BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of Brenda Schulman , Ph.D., Director of the Department of Molecular Machines and Signaling at Max Planck Institute of Biochemistry,

Alex Cadotte, PhD, Former U.S. Food & Drug Administration (FDA) Team Lead for Imaging Software and Division Lead for Software and Digital Health joins MCRA as Associate Director, Software & Digital Health.

Phase 3 randomized withdrawal trial for cardiomyopathy in Barth planned ReCLAIM Phase 1 data presented at ARVO 2021 supports ReCLAIM-2 Phase 2 geographic atrophy trial design; data from fully enrolled ReCLAIM-2 trial expected second quarter of 2022

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Janssen Pharmaceuticals, Inc., (Janssen) part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has delivered written notice of its intent to exercise its option right for ARO-JNJ1.

Brooklyn ImmunoTherapeutics , Inc. (NYSE American: BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders and monogenic diseases, today announced that management will host a conference call on Tuesday, May 25, 2021 at 4:30 p.m. Eastern Time (ET).

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that that the Company will host a virtual key opinion leader (“KOL”) webinar on BX003 for the treatment of inflammatory bowel disease (“IBD”) on Wednesday, May 26, 2021 at 8:00 AM EDT.

Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, announced it has enrolled the first 60 patients in its MET642 Phase 2a trial.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced the appointment of Dr. Olivera Finn and Dr. Mark Frohlich to its Scientific Advisory Board.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the initiation of dosing in the Company’s Phase 1/2 study (MAA-202) of marzeptacog alfa (activated) – known as “MarzAA.” MarzAA is a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa).

Oxford Immunotec, a global, high-growth diagnostics company part of PerkinElmer , today announced that its T-SPOT ® Discovery SARS-CoV-2 kit is being used for T cell testing in the UK COVID-19 Human Challenge Study, a national collaboration including the UK government, the NHS, academia and the private sector.